v3.26.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Summary of Expense Categories Reviewed

The table below summarizes the expense categories reviewed by the CODM for the three months ended March 31, 2026 and 2025:

 

 

 

Three Months Ended
March 31,

 

 

 

2026

 

 

2025

 

External research and development(1)

 

 

 

 

 

 

Ribupatide injection

 

$

(50,571

)

 

$

(4,469

)

KAI-7535

 

 

(4,483

)

 

 

(374

)

KAI-4729

 

 

(410

)

 

 

(232

)

Ribupatide oral

 

 

(361

)

 

 

-

 

Unallocated research and development and other(2)

 

 

(3,574

)

 

 

(796

)

General and administrative(3)

 

 

(4,417

)

 

 

(3,586

)

Personnel related (including stock-based compensation)(4)

 

 

(20,844

)

 

 

(11,001

)

Interest income

 

 

5,716

 

 

 

1,675

 

Other income (expense), net

 

 

79

 

 

 

800

 

Net loss

 

$

(78,865

)

 

$

(17,983

)

 

1)
External research and development is allocated to the Company’s programs, and includes nonclinical, clinical trial, contract manufacturing, non-employee consultant and contractor, and other research and development costs.
2)
Unallocated research and development includes external costs that are not program specific primarily related to consultant and contractor costs, in addition to research and development allocated rent expense and depreciation.
3)
General and administrative includes external costs related to the Company’s executive, finance, legal, and other administrative functions, such as professional fees for legal, patent, consulting, accounting, audit and tax services. General and administrative also includes information technology costs and general and administrative allocated rent expense and depreciation.
4)
Internal costs includes salaries and related costs, including stock-based compensation, for employees.